Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)
Lilly Declares Third-Quarter 2019 Dividend
INDIANAPOLIS, IN -The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding common stock.
The dividend is payable September10, 2019, to shareholders of record at the close of business on August 15, 2019.
AboutEli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.F-LLY
###
Fichier PDF dépôt réglementaire
Titre du document : Lilly Declares Third-Quarter 2019 Dividend Document : http://n.eqs.com/c/fncls.ssp?u=SIXDQWQGGJ
Eli Lilly and Company figure parmi les principaux groupes pharmaceutiques mondiaux. Le CA par domaine thérapeutique se répartit comme suit :
- endocrinologie (57,7%) : produits pour le traitement de l'ostéoporose, du diabète et des problèmes de croissance ;
- oncologie (19,5%) ;
- maladies immunitaires (11,1%) ;
- neurologie (8,4%) : essentiellement médicaments destinés au traitement de la dépression et de la schizophrénie ;
- autres (3,3%).
La répartition géographique du CA est la suivante : Etats-Unis (63,9%), Europe (18,1%), Japon (4,9%), Chine (4,5%) et autres (8,6%).